POSTER PRESENTATION



Open Access

Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal

Mónica Inês^{1*}, Teresa Coelho², Isabel Conceição³, Filipa Duarte-Ramos⁴, Mamede de Carvalho¹, João Costa⁵

From First European Congress on Hereditary ATTR amyloidosis Paris, France. 2-3 November 2015

Background

Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) is a rare, progressive, debilitating and life-threatening neurodegenerative disease. TTR-FAP is a rare disease worldwide. In Europe a disease is defined as rare when it affects less than 1 in 2000 inhabitants. Portugal has the largest cluster worldwide nonetheless recent Portuguese epidemiologic data is lacking. The purpose of this study is to estimate TTR-FAP prevalence in Portugal.

Methods

In Portugal, TTR-FAP patient's medicines utilization is fully funded by National Health Service since 2001. Since March 2013 Portuguese electronic prescription system became more generalized, allowing central monitoring and validation of medicines prescription and dispensing. TTR-FAP anonymized patient's prescription data was requested to Administração Central do Sistema Saúde (ACSS). For each prescription the database has information regarding the local where the medicines were dispensed. Hence, for each patient, the most frequent municipality was identified and used as a proxy for residence. Portuguese total population by municipality was obtained from the official source - Instituto Nacional de Estatística. Prevalence was reported for mainland country and by municipality as number of cases per 2000 inhabitants.

Results

Trough year 2014, a total of 70286 electronic dispensing acts were detected in ACSS database, unravelling a total of 2013 distinctive TTR-FAP patients in Portugal. A prevalence of 0,41 per 2000 inhabitants was estimated for TTR-FAP in Portugal. The disease is currently

¹Instituto de Medicina Molecular, Unidade de Fisiologia Clínica e Translacional, 1649-028, Lisboa, Portugal

Full list of author information is available at the end of the article



Conclusion

We can estimate that TTR-FAP disease has a current prevalence of 0,41 per 2000 inhabitants in Portugal and it is now disseminated across the country being Póvoa de Varzim historically and still the most impacted municipality with 3,95 cases per 2000 inhabitants, nearly ten times higher than overall country prevalence.

Authors' details

¹Instituto de Medicina Molecular, Unidade de Fisiologia Clínica e Translacional, 1649-028, Lisboa, Portugal. ²Centro Hospitalar do Porto, Unidade Corino de Andrade, 4000-436, Porto, Portugal. ³Centro Hospitalar Lisboa Norte, Serviço de Neurologia, 1649-035, Lisboa, Portugal. ⁴Faculdade de Farmácia da Universidade de Lisboa, Departamento de Sócio Farmácia, 1649-003, Lisboa, Portugal. ⁵Instituto de Medicina Molecular, Unidade de Farmacologia Clínica, 1649-028, Lisboa, Portugal.

Published: 2 November 2015

doi:10.1186/1750-1172-10-S1-P21 Cite this article as: Inês *et al.*: Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal. Orphanet Journal of Rare Diseases 2015 10(Suppl 1):P21.



© 2015 Inês et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http:// creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/ zero/1.0/) applies to the data made available in this article, unless otherwise stated.